Leap Therapeutics Inc (NASDAQ:LPTX) has been assigned a consensus broker rating score of 1.33 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company.
Brokerages have set a 1-year consensus price objective of $14.50 for the company and are expecting that the company will post ($0.42) EPS for the current quarter, according to Zacks. Zacks has also given Leap Therapeutics an industry rank of 80 out of 255 based on the ratings given to its competitors.
LPTX has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of Leap Therapeutics from a “hold” rating to a “buy” rating and set a $8.25 target price for the company in a research report on Saturday, October 6th. ValuEngine upgraded shares of Leap Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 30th.
Leap Therapeutics (NASDAQ:LPTX) last issued its earnings results on Wednesday, August 8th. The company reported ($0.50) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.49) by ($0.01). Equities research analysts predict that Leap Therapeutics will post -2.18 earnings per share for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of LPTX. Millennium Management LLC acquired a new stake in shares of Leap Therapeutics in the first quarter valued at about $105,000. Creative Planning acquired a new stake in shares of Leap Therapeutics in the second quarter valued at about $144,000. Point72 Asset Management L.P. acquired a new stake in shares of Leap Therapeutics in the first quarter valued at about $227,000. JPMorgan Chase & Co. raised its position in shares of Leap Therapeutics by 39,223.3% in the first quarter. JPMorgan Chase & Co. now owns 40,503 shares of the company’s stock valued at $336,000 after buying an additional 40,400 shares during the last quarter. Finally, DRW Securities LLC acquired a new stake in shares of Leap Therapeutics in the second quarter valued at about $347,000. Institutional investors and hedge funds own 18.01% of the company’s stock.
About Leap Therapeutics
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. The company's clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.
Featured Article: Terms to Better Understand Call Options
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.